Unknown

Dataset Information

0

Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.


ABSTRACT: PURPOSE:Aside from Gleason sum, few factors accurately identify the subset of prostate cancer patients at high risk for metastatic progression. We hypothesized that epigenetic alterations could distinguish prostate tumors with life-threatening potential. EXPERIMENTAL DESIGN:Epigenome-wide DNA methylation profiling was performed in surgically resected primary tumor tissues from a population-based (n = 430) and a replication (n = 80) cohort of prostate cancer patients followed prospectively for at least 5 years. Metastasis was confirmed by positive bone scan, MRI, CT, or biopsy, and death certificates confirmed cause of death. AUC, partial AUC (pAUC, 95% specificity), and P value criteria were used to select differentially methylated CpG sites that robustly stratify patients with metastatic-lethal from nonrecurrent tumors, and which were complementary to Gleason sum. RESULTS:Forty-two CpG biomarkers stratified patients with metastatic-lethal versus nonrecurrent prostate cancer in the discovery cohort, and eight of these CpGs replicated in the validation cohort based on a significant (P < 0.05) AUC (range, 0.66-0.75) or pAUC (range, 0.007-0.009). The biomarkers that improved discrimination of patients with metastatic-lethal prostate cancer include CpGs in five genes (ALKBH5, ATP11A, FHAD1, KLHL8, and PI15) and three intergenic regions. In the validation dataset, the AUC for Gleason sum alone (0.82) significantly increased with the addition of four individual CpGs (range, 0.86-0.89; all P <0.05). CONCLUSIONS:Eight differentially methylated CpGs that distinguish patients with metastatic-lethal from nonrecurrent tumors were validated. These novel epigenetic biomarkers warrant further investigation as they may improve prognostic classification of patients with clinically localized prostate cancer and provide new insights on tumor aggressiveness. Clin Cancer Res; 23(1); 311-9. ©2016 AACR.

SUBMITTER: Zhao S 

PROVIDER: S-EPMC5199634 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.

Zhao Shanshan S   Geybels Milan S MS   Leonardson Amy A   Rubicz Rohina R   Kolb Suzanne S   Yan Qingxiang Q   Klotzle Brandy B   Bibikova Marina M   Hurtado-Coll Antonio A   Troyer Dean D   Lance Raymond R   Lin Daniel W DW   Wright Jonathan L JL   Ostrander Elaine A EA   Fan Jian-Bing JB   Feng Ziding Z   Stanford Janet L JL  

Clinical cancer research : an official journal of the American Association for Cancer Research 20160629 1


<h4>Purpose</h4>Aside from Gleason sum, few factors accurately identify the subset of prostate cancer patients at high risk for metastatic progression. We hypothesized that epigenetic alterations could distinguish prostate tumors with life-threatening potential.<h4>Experimental design</h4>Epigenome-wide DNA methylation profiling was performed in surgically resected primary tumor tissues from a population-based (n = 430) and a replication (n = 80) cohort of prostate cancer patients followed prosp  ...[more]

Similar Datasets

| S-EPMC5510189 | biostudies-literature
| S-EPMC6120526 | biostudies-literature
| S-EPMC5293735 | biostudies-literature
| S-EPMC8193839 | biostudies-literature
| S-EPMC9780337 | biostudies-literature
| S-EPMC8698937 | biostudies-literature
| S-EPMC6715522 | biostudies-literature
| S-EPMC2799055 | biostudies-literature
| S-EPMC9592923 | biostudies-literature
| S-EPMC3190033 | biostudies-literature